Last reviewed · How we verify

NCT02847143: OTACLA

Ocytocine and Cerebral Activation in Relation With Attachement

Completed Phase 2 Last updated 2 October 2024
What this trial tests

Phase 2 trial testing nasal oxytocin or placebo in Attachement Style in 100 participants. Completed in 27 April 2018.

Timeline
9 April 2015
Primary endpoint
27 April 2018
27 April 2018

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Besancon
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposetreatment
Enrollment100
Start date9 April 2015
Primary completion27 April 2018
Estimated completion27 April 2018
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

Adults 18 to 30, male only, with Attachement Style. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to characterize the cerebral activation modifications related to nasal oxytocin administration during vizualisation of distress images in population of healthy people with different attachement styles.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of fMRI

Trials testing the same drug.

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02847143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing